Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan

NCT05106803 | Completed FDA Drug

• 1 other identifier: Antibiotic profile in Jordan
• Study Type: observational
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan.

Conditions

Bacterial Infections; Antibiotic Resistant Infection; Surgical Site Infection

Keywords

antimicrobial; hospital; post-surgical infection; surgery

Outcome Measures

Primary Outcomes (1)

• Positive culture

  Positive swab culture from the wound

  August 2019 to October 2019

Secondary Outcomes (2)

• Gram stain and type of Bacteria

  August 2019 to October 2019

• Antibiotic Susceptibility

  August 2019 to October 2019

Study Arms (1)

Wound infection

Patients with surgical site infection as diagnosed by the attending physician

Drug: ciprofloxacin

Interventions

ciprofloxacin DRUG

Antibiotics used in vitro n the study

Also known as: trimethoprim-sulfamethoxazole, norfloxacin, erythromycin, chloramphenicol, gentamicin, tetracycline, vancomycin, amoxicillin/clavulanic acid, cefepime, penicillin, ampicillin, clindamycin, oxacillin

Wound infection

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

A hospital-based prospective study was carried out in Public-Teaching Hospital in northern Jordan with a total capacity of 400 beds, All patients meet the criteria of getting post-operative wound infections in different surgical wards and ICUs.

You may qualify if:

• Post-Surgical Wound Infection

Sponsors & Collaborators

• Yarmouk University: lead

Study Sites (1)

Yarmouk University

Irbid, 21163, Jordan

Location

MeSH Terms

Conditions

Bacterial Infections; Surgical Wound Infection

Interventions

Ciprofloxacin; Trimethoprim, Sulfamethoxazole Drug Combination; Norfloxacin; Erythromycin; Chloramphenicol; Gentamicins; Tetracycline; Vancomycin; Amoxicillin-Potassium Clavulanate Combination; Cefepime; Penicillins; Ampicillin; Clindamycin; Oxacillin

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections; Wound Infection; Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Fluoroquinolones; 4-Quinolones; Quinolones; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Sulfamethoxazole; Benzenesulfonamides; Sulfonamides; Amides; Organic Chemicals; Sulfanilamides; Aniline Compounds; Amines; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Sulfones; Sulfur Compounds; Trimethoprim; Pyrimidines; Heterocyclic Compounds, 1-Ring; Drug Combinations; Pharmaceutical Preparations; Macrolides; Polyketides; Lactones; Propylene Glycols; Glycols; Alcohols; Nitrobenzenes; Nitro Compounds; Aminoglycosides; Glycosides; Carbohydrates; Tetracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds; Glycopeptides; Glycoconjugates; Peptides; Amino Acids, Peptides, and Proteins; Clavulanic Acid; Clavulanic Acids; beta-Lactams; Lactams; Amoxicillin; Penicillin G; Cephalosporins; Thiazines; Lincomycin; Lincosamides; Pyrrolidines

Study Officials

• Raed M Ennab

  Department of Clinical Sciences, Faculty Of Medicine, Yarmouk University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: October 24, 2021
• First Posted: November 4, 2021
• Study Start: August 1, 2019
• Primary Completion: October 1, 2019
• Study Completion: October 1, 2019
• Last Updated: November 4, 2021

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

JO (1)